ImmunityBio, Inc. 13D

Patrick Soon‑Shiong and affiliated entities report a roughly 64.8% beneficial stake in ImmunityBio, Inc. on an amended Schedule 13D, updating ownership calculations and existing agreements without indicating new activist actions.

This Schedule 13D/A reflects that Patrick Soon‑Shiong, together with affiliated entities including Cambridge Equities, LP, MP 13 Ventures, LLC, NantWorks, LLC, Nant Capital, LLC, California Capital Equity, LLC and related subsidiaries and a family foundation, may be deemed to beneficially own approximately 64.8% of ImmunityBio, Inc.’s common stock (745,518,285 shares including options and note conversion rights) as of July 31, 2026, primarily through existing holdings and the right to acquire additional shares via options and a promissory note; the amendment updates beneficial ownership calculations and confirms existing joint filing, nominating and registration rights arrangements without disclosing new activist plans or changes in control intentions.

Filing Facts

CIK

1326110

Ticker

IBRX

Form

13D

Source Type

fda

Accession

0001193125-26-338651

Alert Tier

6